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Abstract Acquiring the immune-mediated apoptosis and the ability to regulate the cytotoxic 
immune response are the main phenomena playing fundamental roles in such situ-
ations as neoplasm survival and creation of immune tolerance during pregnancy. 
The aim of this study was to investigate these phenomena through the evaluation 
of metallothionein and RCAS1 proteins in neoplasm and its healthy environment 
(clear surgical margin), physiological conditions in placenta and its environment 
(decidua) and the comparison to non-neoplasmatic lesions originating from the 
environment (nasal polyps, endometriosis). We have shown that the growth of 
RCAS1 expression was simultaneous to the infiltration of activated immunological 
cells of tumor environment as well as decidua. The activity of immunological cells 
was in our study selectively suppressed. Metallothionein expression growth was also 
observed in healthy tumors stroma and in decidua probably in response to the grow-
ing cytotoxic activity and tumor spread. Alterations in RCAS1 and Metallothionein 
expression seem to be associated with local immune dysfunction in nasal polyps 
and endometriosis. In conclusion, the ability to compensate the growing cytotoxic 
immune response is physiologically observed in decidua, the lost of this ability in 
tumor environment might participate in the development of tumor spread.
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1. Introduction 
Immune tolerance
Immune tolerance is a continuous process condi-
tioned by various factors including interaction between 
neoplasmatic cells/trophoblast cells and immune cells. It 
has been described a participation of 64 antigens in the 
process of ovarian cancer cells escape from host immuno-
logical surveillance [1]. Despite of the investigation on so 
many factors participating in tumor escape from immune 
surveillance, this process is still not clearly understood. 
The understanding of this process has to be reinforced 
by the tumor environmental behavior [2–4]. The result 
of neoplasm development is not only determined by the 
uncontrolled proliferation but also the disintegration of 
the origin tissue takes place. 
The regulation of the number of cells is determined 
by apoptosis. Physiologically tissue can be remodeled by 
apoptosis as a response to external factors. In 1972 JF. 
Kerr observed the possibility of recycling of apoptotic 
bodies by adjacent normal cells [5]. The genes amplifica-
tion originating from apoptotic bodies was confirmed [6]. 
DNA and mRNA were described to be separately packed 
in various apoptotic bodies what indicates the existence 
of biological material recycling through apoptosis [7]. It 
was also confirmed that a metastasis may develop from 
one single cell or even from mutated DNA originating 
from apoptotic body [8]. The effect of immune cells 
activity is normally the elimination of impaired cells 
through apoptosis; the apoptosis of neoplasmatic cell 
results in the development of apoptotic body containing 
mutated DNA which may also be used by normal cell and 
this way the phenomenon of apoptosis may be a step for 
tumor spread instead of the proper immune cells activity 
target. What is the biological reason of this process? Im-
mune tolerance during pregnancy is not only the process 
of inhibition of immune response by trophoblast cells 
but also by the presence of apoptotic bodies originating 
from fetal cells in maternal circulation [9]. The usage of 
fetal genetic material (amplification) by mother was also 
confirmed [10,11]. It was also shown that fragments of 
these cells are necessary not only for the selective inhibi-
tion of maternal immune response, because these frag-
ments express Fas-ligand (Fas-L/CD95-ligand/CD178), 
induces apoptosis of Fas (CD95/Apo-1) expressing 
cells [12] but also are responsible for the generating 
an adequate maternal cytotoxic response necessary for 
proper pregnancy development. The phenomenon of 
maternal immune tolerance during pregnancy should 
be understood not as a general inhibition of maternal 
immune system but rather as the selective suppression 
of activated cytotoxic cells. Since apoptotic bodies seem 
to play such an important role in the process of immune 
tolerance the location of their source (maternal-fetal 
interface and the margin of neoplasmatic tissue as well 
as tissues potentially able to use this cellular material) 
has to be taken into consideration. Similarly immune 
tolerance develops for the growing neoplasm, which can 
avoid immune recognition and evade immune mediated 
apoptosis despite the infiltration of activated immune 
cells- TIL (tumor infiltrating lymphocytes). Therefore 
the mechanisms responsible for the host toleration for 
to the high number of immune cytotoxic cells in the 
vicinity of tumor seem to be interesting. The dissemina-
tion of tumor cells (tumor spread through the environ-
ment) may be determined by the lost of tissue ability 
to compensate the cytotoxic immune response. Similar 
physiological process is observed during pregnancy. 
Decidualization is a process where the accumulation of 
cytotoxic active cells is observed [13]. The coexistence 
of endometrium and immune cells (integrity of tissue) is 
determined by the ability of endometrial cells to regulate 
cytotoxic activity and the resistance to immune mediated 
apoptosis. The highest concentration of immune cells is 
concomitant with ovum implantation and is responsible 
for the restriction of trophoblast cells invasion within 
decidua [14]. The interaction between endometrial 
cells and the immune cells without ovum implantation 
results in menstruation bleeding. When damaged ovum 
implantation occurs this interaction results in abortion 
[15–16]. Many factors of immune-modulating activ-
ity are known present in endometrium (Interleukin-15, 
Interleukin-13, Tumor growth factor-TGF, TNF-alpha, 
Interleukin-11, Fas, Fas-L and others) [17–20]. These 
factors are strongly secreted beginning with the implan-
tation window through the whole pregnancy duration. 
The participation of decidual cells in the process of im-
mune tolerance during pregnancy has not been precisely 
explained yet. The proportion of decidual and placental 
inhibiting activities in the maternal immune tolerance 
during pregnancy still remains unclear. 
The immune tolerance during pregnancy has been 
compared to the phenomenon of immune tolerance to 
neoplasm [21] therefore we have performed molecular 
analysis of proteins expression responsible for the regu-
lation of immune cytotoxic activity and the resistance 
to immune mediated apoptosis in the environment of 
trophoblast and neoplasmatic cells: decidua and clear 
surgical margin of malignant neoplasm. The expression 
of these factors was additionally evaluated in non-neo-
plasmatic lesions based on immune dysfunction: nasal 
polyps and endometriosis. 
2. Results
The alteration of RCAS1 and Metallothionein 
expression regarding immune cells infiltration
RCAS1, which was until now thought to be responsible 
for tumor escape from immune surveillance in various 
human cancer cells [22,23] seems to be an important fac-
tor for cytotoxic activity regulation in the endometrium 
[24]. It has been reported to be expressed with high fre-
quency in breast, lung, larynx and pharynx, gallbladder, 
ovarian, uterine, bile duct cancer cells, in Reed Sternberg 
cells and erythroid progenitor cells [25–31]. The RCAS1 
protein acts as a ligand for a putative receptor present 
in various human cells including normal peripheral 
lymphocytes such as T, B, and NK (natural killer) cells 
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[22]. RCAS1 inhibits growth of receptor expressing cells 
in vitro and in vivo and induces apoptotic cell death 
through activation of caspase 3 and collapse of mito-
chondrial transmembrane potential [31]. The RCAS1 
high expression in gallbladder, cervical and lung cancers 
increased with tumor stage and was linked to the depth 
of tumor invasion, to lymph node metastases, and was an 
independent unfavorable prognostic factor [25,26,32]. 
RCAS1 is however not only the marker of tumor pro-
gression. The expression of RCAS1 recognized in the 
bone marrow, Waldeyer’s ring, placenta, endometrium, 
autoimmune liver disease and the tubal mucosa indicates 
its role in immune cells regulation [33–37]. 
Metallothionein (MT) is a cysteine-rich, low molecu-
lar weight cytoplasmic protein with functional roles in 
cell growth and differentiation [38]. MT immunoreactiv-
ity was prominent in cancer tissue, presenting a nuclear 
pattern of staining being inversely correlated with the 
apoptotic index [39]. It is also known that perinuclear 
MT location is important for protective function of MT 
against DNA damage and apoptosis [40,41], through 
the regulation of zinc-dependent enzymes and proteins 
activity. MT expression has been linked to reduced 
apoptosis in carcinoma cells [42,43,44]. MT participates 
in the regulation of DNA-repair process by PAPR-1 (the 
polyADP-ribose-polymerase-1) [45]. MT was found 
to interact specifically with subunit of NF-κB (nuclear 
factor κB) in breast cancer cell line, and inhibit the bind-
ing of NF-κB to DNA following TNF (tumor necrosis 
factor) activation [46]. Its expression was observed in 
the endometrium, in endometrial cancer and ovarian 
endometriosis [24,47–49]. MT expression seems to pro-
tect endometrial cells against apoptosis enabling them 
to acquire resistance to immune-mediated apoptosis 
[24]. MT expression is recognized as a useful prognostic 
tool, especially in invasive ductal breast carcinoma [50]. 
In head and neck cancer high MT immunoreactivity 
correlated with increased local and regional recurrence, 
resulting in poor prognosis [51]. 
2.1 Endometrium according to menstrual  
cycle changes 
An increase of MT and RCAS1 expression was iden-
tified during the decidualization. The peak of MT and 
RCAS1 expression was observed during mid-secretory 
cycle phase. The higher MT and RCAS1 expressions 
were related to the growth of number of CD56 positive 
cells (natural killer cells) and the increase of CD69 (early 
activation marker of lymphocytes) expression [24,52]. 
In contrary, the growth of RCAS1 expression during the 
secretory cycle phase was associated with a decrease of 
CD25 (receptor for interleukin-2) expression [53]. 
2.2 Fallopian tube mucosa during implantation  
of ectopic pregnancy
Significantly more abundant CD56 and CD69 posi-
tive cells were observed in tubal mucosa during the tubal 
rupture in comparison to unruptured tubal ectopic preg-
nancy. In contrast to spontaneous abortion the growth of 
immune cytotoxic activity was not related to an adequate 
increase of MT expression in tubal implantation site. MT 
expression during tubal rupture in tubal mucosa has been 
significantly lower than in decidua during spontaneous 
abortion. In both cases the level of CD 56 and CD69 
expression was comparable [54].
2.3 The initiation of labor 
The maternal-fetal interface during the labor is typi-
fied by high cytotoxic activity [55,56]. The results of our 
research suggest that this growth comes from the drop of 
suppressive placental function which is observed during 
spontaneous beginning of the labor. Significantly lower 
RCAS1 expression has been observed during spontane-
ous vaginal labor in comparison to induced vaginal labor 
[35,57,58]. The placental RCAS1 expression was decreas-
ing with the uterine cervix ripening during cesarean 
sections. Significant drop of RCAS1 has been observed 
when the cervix was ripen over 2cm [59]. The level of 
immune tolerance during the initiation of labor was not 
related to the fetal maturity [60]. The growth of cytotoxic 
response during the labor was related to the growth of 
MT expression in decidua [manuscript in preparation]. 
2.4 The retained placental tissue 
The retained placental tissue observed during the 
third stage of labor may indicate that the process of 
placental detachment which is based on immune cells 
activity was not finished when the cervix was totally 
ripen. This was confirmed by the evaluation of placental 
RCAS1 level. The RCAS1 placental level was significantly 
higher in cases of retained placental tissue in comparison 
to spontaneous labor [61]. 
2.5 Endometriosis
Ovarian ectopic endometrial cells in our studies were 
typified by a decreased MT and RCAS1 expression levels 
with higher number of CD56, CD69 and CD25 positive 
cells in comparison to secretory endometrial cells [24,62]. 
This observation seems to confirm NK dysfunction de-
scribed in endometriosis [63] as well as indicates the pos-
sibility of endometriosis development as a phenomenon 
secondary to the endometrium ability to coexistence 
with active immune cells. This interpretation remains in 
compliance with the observation of increased I-human 
lymphocyte antigens (hLA-I) expression in endometrial 
cells during retrograde menstruation which blocks NK 
mediated lysis [64]. In scar endometriomas (after cesar-
ean section) MT expression as well as CD25 antigens 
expressions differed from that observed in ovarian 
endometriosis, while RCAS1, CD56 and CD69 antigens 
expressions remained at comparable levels [62]. These 
differences led us to a conclusion that the development 
of scar endometriosis may be reinforced by immune 
tolerance during pregnancy because it occurs more 
frequently after elective cesarean section [65]. Addition-
ally the presence of RCAS1 positive macrophages were 
identified only in ovarian endometriosis, they were not 
present in scar endometriosis or secretory endometrium. 
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Therefore the physiological process of immune tolerance 
started during decidualization might participate in per-
sisting of scar endometriomas cells [62,65,66]. 
2.6 The development of local lymph nodes metastases 
higher MT expression was found in breast cancer and 
head and neck cancer stroma in cases with the presence 
of local lymph nodes metastases in comparison to cases 
without lymph nodes metastases [67]. RCAS1 expression 
was also observed to be higher in head and neck cancer 
stroma in patients with the presence of lymph nodes 
metastases in comparison to patients without metastases 
[32]. This relation was not observed in breast cancer. 
The predominant cells among TIL in breast cancer were 
CD3 positive cells while no CD56 positive cells were 
observed. The number of CD3 and CD25 positive cells 
was significantly lower in the group of patients with the 
presence of lymph node metastases in comparison to 
patients without metastases although no differences in 
CD69 antigen expression were observed between these 
two groups of patients [29,68]. 
2.7 Nasal polyps
Nasal polyps are a benign growth of nasal mucosa 
based on immune mediated dysfunction [69,70]. In histo-
pathological examination nasal polyps were in our study 
divided regarding the predominant cells infiltration and 
three groups of polyps were indicated: eosinophilic nasal 
polyps, neutrophilic nasal polyps and lymphocytic nasal 
polyps. Within these groups of polyps different resistance 
to immune mediated apoptosis was observed and an abil-
ity to regulate the immune cytotoxic response assessed 
by the expression of RCAS1 protein was noticed in nasal 
polyps. The higher RCAS1 expression was observed in 
lymphocytic nasal polyps in comparison to eosinophilic 
and higher in eosinophilic than in neutrophilic nasal 
polyps. Moreover RCAS1- positive macrophages were 
shown in the nasal polyps stroma where increased im-
mune infiltration was present in pseudocystic structures 
[71]. Alterations in the resistance to immune mediated 
apoptosis enabling the polypoid tissue growth as well as 
the ability to regulate the activity of infiltrating immune 
cells were observed with respect to the type of immune 
cells infiltration. 
3. Comment
The regulation of TIL activity in tumor adjacent tis-
sue is currently under consideration [72,73]. Chang has 
presented the results of analysis of killer inhibitory re-
ceptors (KIRs) expression on TIL in human endometrial 
cancer and indicated that tumor might itself provide the 
increase of expression of NKG2A/CD94 on TIL which 
results in the restriction of their activity [74]. Similarly 
Ponte has noticed NKG2a expression alterations in pe-
ripheral blood NK cells derived from pregnant women 
and indicated that these changes result from the activity 
of trophoblast cells [75]. The participation of KIRs espe-
cially through the interaction with hLA-G1 in immune 
tolerance during pregnancy is well known [76]. The 
observed decreased expression of the IL-2 receptor in 
TIL in tissue adjacent to the tumor in breast and cervical 
cancers has been interpreted by Sheu as a result of exis-
tence of TIL selective suppression phenomenon [77]. Our 
results remain in concordance with aforementioned and 
selective suppression in our studies seems to be higher 
in patients with the presence of lymph node metastases. 
We posit that RCAS1 might be a factor responsible or 
facilitating the selective suppression phenomenon in 
tumor environment. Similarly the phenomenon of this 
selective suppression is observed during decidualization 
and seems to be a part of immune tolerance during 
pregnancy. The growth of CD69 antigen expression in 
secretory endometrium co-existing with decrease of 
CD25 antigen expression was identified in our study and 
remains in compliance with Saito and ho results [78,79]. 
Saito indicated that these lymphocytes during secretory 
cycle phase remain rather more activated than in a resting 
state although CD25 expression was found to be lower in 
this study [79]. This might easily be explained by selec-
tive suppression phenomenon using RCAS1 expression. 
In sum, the selective suppression phenomenon is neces-
sary for the preservation of the activated lymphocytes 
in decidua necessary for the restriction of trophoblast 
invasion assuring the inhibition of immune response 
against decidual cells. This phenomenon is necessary 
also for the assuring of tissue integrity during growing 
cytotoxic response against tumor cells and the loss of this 
ability may lead to tumor spread. 
The interaction between stroma/decidua and immune 
cells is also observed in immune mediated diseases. In 
both endometriosis and nasal polyps derived from the 
environment of these lesions the presence of RCAS1 
positive macrophages was observed. RCAS1 positive 
macrophages have been only observed in bone marrow 
where they were proved to participate in the maturation of 
progenitor cells [31] or in hodgkin disease [80]. Recently, 
RCAS1 positive macrophages were described in immune 
mediated liver diseases [81]. The possible participation 
of RCAS1-positive macrophages in the etiology of im-
mune-mediated diseases may indicate the importance of 
selective cytotoxic suppression phenomenon. 
The results presented above may confirm the simi-
larity of cancer environment to decidua. The key way 
to differentiate between these two phenomena is their 
reversibility in pregnancy during the labor. Although 
the inhibition of maternal immune response by placenta 
disappears, an adequate immune cytotoxic activity has 
to be assured and is maintained by the suppressive 
decidual cells activity. The growth of the resistance to 
immune mediated apoptosis occurs and is necessary 
for the coexistence of immune cells with decidual cells. 
The increase of MT expression has been observed in our 
study within decidual cells during spontaneous abortion 
and preterm births however, the lack of MT expression 
increase concomitant with growing cytotoxic response 
within tubal mucosa has resulted in tubal rupture. The 
tumor environment is typified by the MT overexpression 
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which may be the demonstration of physiological local 
processes regulation destruction. 
In conclusion, selective suppression of active immune 
cells and resistance to immune mediated apoptosis in de-
cidua are a part of immune tolerance during pregnancy 
phenomenon and are also observed in tumor environ-
ment. The loss of the ability to compensate the growing 
cytotoxic immune response in the environment might 
participate in the development of tumor spread.
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